UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 54

Sortiert nach

Effectiveness of dolutegravir‐based regimens as either first‐line or switch antiretroviral therapy: data from the Icona cohort

Journal of the International AIDS Society, 2019-01, Vol.22 (1), p.e25227-n/a

2019

Volltextzugriff (PDF)

Evolution of transmitted HIV‐1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016

HIV medicine, 2018-10, Vol.19 (9), p.619-628

2018

Volltextzugriff (PDF)

Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results

AIDS (London), 2014-09, Vol.28 (15), p.2269-2279

2014

Volltextzugriff (PDF)

Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial

Journal of antimicrobial chemotherapy, 2016-06, Vol.71 (6), p.1637-1642

2016

Volltextzugriff (PDF)

Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe

BMC infectious diseases, 2014-07, Vol.14 (1), p.407-407, Article 407

2014

Volltextzugriff (PDF)

Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort

Journal of antimicrobial chemotherapy, 2013-01, Vol.68 (1), p.200-205

2013

Volltextzugriff (PDF)

Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010

Clinical microbiology and infection, 2012-08, Vol.18 (8), p.E299-E304

2012

Volltextzugriff (PDF)

Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients

Retrovirology, 2012-10, Vol.9 (1), p.81-81, Article 81

2012

Volltextzugriff (PDF)

Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting

Journal of antimicrobial chemotherapy, 2009-09, Vol.64 (3), p.616-624

2009

Volltextzugriff (PDF)

Replication Capacity in Relation to Immunologic and Virologic Outcomes in HIV-1-Infected Treatment-Naive Subjects

Journal of acquired immune deficiency syndromes (1999), 2009-03, Vol.50 (3), p.250, Article 250

2009

Volltextzugriff (PDF)

Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort

PloS one, 2016-10, Vol.11 (10), p.e0164753

2016

Volltextzugriff (PDF)

Unexpected CD4 decay, hidden adherence gaps, resilience, and the need for long-acting therapy in a single HIV outpatients' cohort

AIDS care, 2024-07, Vol.36 (7), p.864-869

2024

Volltextzugriff (PDF)

Choosing appropriate pharmacotherapy for drug-resistant HIV

Expert opinion on pharmacotherapy, 2019-04, Vol.20 (6), p.667-678

2019

Volltextzugriff (PDF)

The future of long-acting cabotegravir plus rilpivirine therapy: deeds and misconceptions

International journal of antimicrobial agents, 2022-09, Vol.60 (3), p.106627-106627, Article 106627

2022

Volltextzugriff (PDF)

Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding

Journal of acquired immune deficiency syndromes (1999), 2021-11, Vol.88 (3), p.234

2021

Volltextzugriff (PDF)

Drug-drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment

Expert opinion on drug metabolism & toxicology, 2019-03, Vol.15 (3), p.245-252

2019

Volltextzugriff (PDF)

A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data

BMC infectious diseases, 2017-09, Vol.17 (1), p.658-7, Article 658

2017

Volltextzugriff (PDF)

Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection

Expert opinion on pharmacotherapy, 2018-01, Vol.19 (1), p.65-77

2018

Volltextzugriff (PDF)

Brief Report: Impact of the COVID-19 Pandemic on Virological Suppression in People Living With HIV Attending a Large Italian HIV Clinic

Journal of acquired immune deficiency syndromes (1999), 2021-11, Vol.88 (3), p.299

2021

Volltextzugriff (PDF)

Darunavir/cobicistat for the treatment of HIV-1: a new era for compact drugs with high genetic barrier to resistance

Expert opinion on pharmacotherapy, 2015-11, Vol.16 (17), p.2689-2702

2015

Volltextzugriff (PDF)

Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV‐1 replication

HIV medicine, 2018-08, Vol.19 (7), p.452-454

2018

Volltextzugriff (PDF)

Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients

Viruses, 2023-05, Vol.15 (5), p.1123

2023

Volltextzugriff (PDF)

Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients

International journal of antimicrobial agents, 2019-12, Vol.54 (6), p.728-734

2019

Volltextzugriff (PDF)

Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV‐infected patients in clinical practice: results from a multicentre, observational study

HIV medicine, 2019-02, Vol.20 (2), p.164-168

2019

Volltextzugriff (PDF)

Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice

AIDS research and human retroviruses, 2020-01, Vol.36 (1), p.4

2020

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Aktive Filter

ThemaHiv

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(53)
Berichte
(1)

Sprache

Englisch
(54)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effectiveness of dolutegravir‐based regimens as either first‐line or switch antiretroviral therapy: data from the Icona cohort

Evolution of transmitted HIV‐1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016

Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results

Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial

Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe

Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort

Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010

Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients

Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting

Replication Capacity in Relation to Immunologic and Virologic Outcomes in HIV-1-Infected Treatment-Naive Subjects

Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort

Unexpected CD4 decay, hidden adherence gaps, resilience, and the need for long-acting therapy in a single HIV outpatients' cohort

Choosing appropriate pharmacotherapy for drug-resistant HIV

The future of long-acting cabotegravir plus rilpivirine therapy: deeds and misconceptions

Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding

Drug-drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment

A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data

Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection

Brief Report: Impact of the COVID-19 Pandemic on Virological Suppression in People Living With HIV Attending a Large Italian HIV Clinic

Darunavir/cobicistat for the treatment of HIV-1: a new era for compact drugs with high genetic barrier to resistance

Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV‐1 replication

Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients

Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients

Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV‐infected patients in clinical practice: results from a multicentre, observational study

Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice

Aktive Filter

Suchergebnisse filtern